UCL Business PLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:UCL Business PLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014080
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
UCL Business PLC (UCLB), a subsidiary of University College London is a technology transfer company that supports and markets research and innovations. The company offers licensing technologies and innovations, creates shared risk joint venture businesses, and promotes and supports the transfer into industry of expertise and knowledge over a wide range of disciplines. It provides commercial expertise, legal advice, and administrative support. UCLB operates in creating spinout businesses in new industries. The company offers services such as contractual advice and formalization, business plan development, and others. It also provide technology licensing, contract negotiation and project management services, among others. The company serves biopharma, engineering and physical sciences companies. UCLB is headquartered in London, the UK.

UCL Business PLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
UCL Business PLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
UCL Business PLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
UCL Business PLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
UCL Business PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
UCL Business PLC, Medical Devices Deals, 2011 to YTD 2017 9
UCL Business PLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
UCL Business PLC, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 12
Puridify Raises USD3.4 Million in Series A Financing 13
Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 14
Puridify Raises USD1.43 Million in Seed Funding 15
Canbex Therapeutics Raises US$3 Million In Venture Financing 16
Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round 17
Partnerships 18
UCL Business Forms Joint Venture with Syncona 18
Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations 19
UCL Ear Institute And UCL Business Enter Into Co-Developemnt Agreement With Autifony Therapeutics 20
UCL Business And National Centre for Young People Enters Into Commercialization Agreement With Special Products For Epistatus 21
Licensing Agreements 22
BioKier Enters into Licensing Agreement with UCL Business 22
Autolus Enters into Licensing Agreement with UCL Business 23
Oxford Pharmascience Extends Licensing Agreement With UCL Business 24
Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology 25
University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology 26
UCL Business Enters Into Licensing Agreement With Periowave Dental Technologies 27
UCL Business PLC – Key Competitors 28
UCL Business PLC – Key Employees 29
UCL Business PLC – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Joint Venture 30
Recent Developments 31
Strategy And Business Planning 31
May 03, 2016: UCLB And F-Prime Launch Orchard Therapeutics To Treat Rare Childhood Diseases 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
UCL Business PLC, Pharmaceuticals & Healthcare, Key Facts, 2016 2
UCL Business PLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
UCL Business PLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
UCL Business PLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
UCL Business PLC, Deals By Therapy Area, 2011 to YTD 2017 8
UCL Business PLC, Medical Devices Deals, 2011 to YTD 2017 9
UCL Business PLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 12
Puridify Raises USD3.4 Million in Series A Financing 13
Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 14
Puridify Raises USD1.43 Million in Seed Funding 15
Canbex Therapeutics Raises US$3 Million In Venture Financing 16
Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round 17
UCL Business Forms Joint Venture with Syncona 18
Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations 19
UCL Ear Institute And UCL Business Enter Into Co-Developemnt Agreement With Autifony Therapeutics 20
UCL Business And National Centre for Young People Enters Into Commercialization Agreement With Special Products For Epistatus 21
BioKier Enters into Licensing Agreement with UCL Business 22
Autolus Enters into Licensing Agreement with UCL Business 23
Oxford Pharmascience Extends Licensing Agreement With UCL Business 24
Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology 25
University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology 26
UCL Business Enters Into Licensing Agreement With Periowave Dental Technologies 27
UCL Business PLC, Key Competitors 28
UCL Business PLC, Key Employees 29
UCL Business PLC, Subsidiaries 30
UCL Business PLC, Joint Venture 30

★海外企業調査レポート[UCL Business PLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Eurobank Ergasias SA:企業のM&A・事業提携・投資動向
    Eurobank Ergasias SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eurobank Ergasias SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Churchill Downs Incorporated:企業の戦略・SWOT・財務情報
    Churchill Downs Incorporated - Strategy, SWOT and Corporate Finance Report Summary Churchill Downs Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • SymBio Pharmaceuticals Ltd (4582):企業の財務・戦略的SWOT分析
    Summary SymBio Pharmaceuticals Ltd (SymBio) is a biopharmaceutical company that develops and markets anti-cancer drug candidates. Its pipeline product portfolio includes Treakisym (SyB L-0501), an anti-cancer agent used for the treatment of non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and chr …
  • Chimerix Inc (CMRX):企業の財務・戦略的SWOT分析
    Summary Chimerix Inc (Chimerix) is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s brincidofovir is an oral nucleotide analog to treat dsDNA viruses, adenovirus, cytomegalovirus, BK virus and herpes simplex viruses. Chimer …
  • Magnitogorsk Metallurgicheskiy Kombinat:企業の戦略・SWOT・財務情報
    Magnitogorsk Metallurgicheskiy Kombinat - Strategy, SWOT and Corporate Finance Report Summary Magnitogorsk Metallurgicheskiy Kombinat - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • North Energy ASA (NORTH):企業の財務・戦略的SWOT分析
    Summary North Energy ASA (North Energy) is an upstream oil and gas company that provides exploration and development services in Norwegian Continental Shelf (NCS). The company’s services include oil and gas exploration and development, license mapping and drilling programs, and conducting geological …
  • Talwalkars Better Value Fitness Ltd (TALWALKARS):企業の財務・戦略的SWOT分析
    Talwalkars Better Value Fitness Ltd (TALWALKARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Advanced Digital Broadcast SA:企業の戦略的SWOT分析
    Advanced Digital Broadcast SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Country Road Group Pty Ltd:企業の戦略的SWOT分析
    Country Road Group Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • GE Healthcare LLC-医療機器分野:企業M&A・提携分析
    Summary GE Healthcare LLC (GE Healthcare) a business unit of General Electric Company, is a global medical device provider that designs, develops, manufactures, and distributes diagnostic imaging and clinical systems; products and services for drug discovery, biopharmaceutical manufacturing and cell …
  • Symic Biomedical Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Symic Biomedical Inc (Symic Biomedical) is a biopharmaceutical company that develops new therapeutics focused on matrix biology. The company’s pipeline products include SB-030 and SB-061. Its SB-030 is a clinical candidate used for the prevention of peripheral vascular diseases or vein graft …
  • Appili Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Appili Therapeutics Inc (Appili Therapeutics) is a bio-pharmaceutical company developing and commercializing anti-infective drugs for the treatment of infectious diseases and drug-resistant pathogens. Its pipeline products include ATI-1501, an oral suspension antibiotic liquid reformulation …
  • HIL Limited (HIL):企業の財務・戦略的SWOT分析
    HIL Limited (HIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • TMRC Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary TMRC Co Ltd (TMRC) is a biopharmaceutical company that develops and markets anti-cancer and cancer related products. The company’s products include tamibarotene Am-80, TOS-80T, OMS0728, and others. Its tamibarotene is a synthetic retinoid, which is designed to develop drug-able properties of …
  • T2 Biosystems Inc (TTOO):企業の財務・戦略的SWOT分析
    Summary T2 Biosystems Inc (T2 Biosystems) is a provider of clinical diagnostic products in the field of in vitro diagnostics. The company’s T2 magnetic resonance technology allows direct detection in complex samples such as whole blood, serum, plasma, sputum and urine. It offers T2HemoStat panel, T2 …
  • Ultrastroy Eood:企業の戦略的SWOT分析
    Ultrastroy Eood - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Athabasca Oil Corp (ATH):石油・ガス:M&Aディール及び事業提携情報
    Summary Athabasca Oil Corp (Athabasca) is an upstream energy company which focuses on exploration, development and production of bitumen, light oil and liquids-rich natural gas from oil sands and related assets. The company employs multi-stage fracturing and horizontal drilling technology from uncon …
  • Airgas, Inc.:企業のM&A・事業提携・投資動向
    Airgas, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Airgas, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Airports of Thailand Plc (AOT):企業の財務・戦略的SWOT分析
    Airports of Thailand Plc (AOT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Dermira Inc (DERM):企業の財務・戦略的SWOT分析
    Summary Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆